Center for Drug Evaluation and Research

Table of Contents

Viagra (Sildenafil)

"Joint Clinical Review" for NDA-20-895

Table of contents

Section 1. Materials utilized in review 1

Section 1.1. Materials from NDA/IND 1

Section 1.2. Related reviews or consults 1

Section 1.3. Other resources 1

Section 2. Background 2

Section 2.1. Indication 2

Section 2.2. Information from related pharmacologically related agents 2

Section 2.3. Administrative history 2

Section 2.4. Proposed labeling 2

Section 2.5. Foreign marketing 2

Section 2.6. Other background information 2

Section 3. Chemistry, manufacturing, and controls 3

Section 3.1. Basis of review 3

Section 3.2. Structure 3

Section 3.3. Deficiencies 3

Section 4. Animal pharmacology 4

Section 4.1. Basis of review 4

Section 4.2. Mechanism of action 4

Section 4.2.1. Screening for other activities 4

Section 4.3. Pharmacokinetics 5

Section 4.4. Toxicology 5

Section 4.4.1. Genetic toxicity 5

Section 4.4.2. Single-dose 5

Section 4.4.3. Sub-chronic/chronic 5

Section 4.4.3.1. Oral 5

Section 4.4.3.1.1. Rats 5

Section 4.4.3.1.2. Dogs 6

Section 4.4.3.1.3. Mice 6

Section 4.4.3.2. Intravenous 6

Section 4.4.3.2.1. Rats 6

Section 4.4.3.2.2. Dogs 6

Section 4.4.4. Chronic 6

Section 4.4.4.1. Rats 6

Section 4.4.4.2. Mice 6

Section 4.4.5. Special toxicity studies 6

Section 4.4.6. Safety margin 6

Section 4.5. Summary of significant findings 7

Section 5. Description of clinical data sources 8

Section 5.1. Primary source data 8

Section 5.1.1. Study type and design and subject enumeration 8
Section 5.1.1.1. Controlled studies 8
Section 5.1.1.2. Clinical pharmacology 9
Section 5.1.1.3. Open-label extensions 11
Section 5.1.1.4. Studies not reviewed in detail 12
Section 5.1.2. Enumeration 13
Section 5.1.3. Demographics 13
Section 5.1.4. Extent of exposure 14
Section 5.1.4.1. Placebo-controlled experience 14
Section 5.1.4.2. Open-label experience 15
Section 5.1.4.3. Safety updates 15

Section 5.2. Secondary source data 15
Section 5.2.1. Other studies 15
Section 5.2.2. Post-marketing experience 15
Section 5.2.3. Literature 15

Section 5.3. Adequacy of clinical experience 15

Section 5.4. Data quality and completeness 15

Section 6. Clinical pharmacology and biopharmaceutics 16

Section 6.1. Bioavailability/bioequivalence 16
Section 6.1.1. Absolute bioavailability 16
Section 6.1.2. Food effects 16
Section 6.1.3. Bioequivalence 16

Section 6.2. Pharmacokinetics 16
Section 6.2.1. Single-dose pharmacokinetics 16
Section 6.2.2. Multiple-dose pharmacokinetics 17
Section 6.2.3. ADME 17
Section 6.2.4. Plasma level-dose relationship 18
Section 6.2.5. Concentrations in semen 18
Section 6.2.6. Protein binding 18

Section 6.3. Special populations 19
Section 6.3.1. Renal impairment 19
Section 6.3.2. Hepatic impairment 19
Section 6.3.3. Age 19
Section 6.3.4. Diabetes 20
Section 6.3.5. Erectile dysfunction 20

Section 6.4. Drug interactions 20
Section 6.4.1. Tolbutamide 20
Section 6.4.2. Warfarin 20
Section 6.4.3. Ethanol 20
Section 6.4.4. Calcium channel blockers 20
Section 6.4.5. Cimetidine 20
Section 6.4.6. Maalox 20
Section 6.4.7. Erythromycin 20
Section 6.4.8. CYP3A4 inducers 21
Section 6.4.9. Diuretics 21
Section 6.4.10. β-blockers 21
Section 6.4.11. CYP2C9 inhibitors 21
Section 6.4.12. CYP2D6 inhibitors 21
Section 6.4.13. ACE inhibitors and angiotensin II antagonists 21

Section 6.4.14. Inhibition of CYP by sildenafil and UK-103,320 21

Section 6.5. Population pharmacokinetic analysis 21

Section 6.6. Pharmacokinetic/pharmacodynamic relationships 21

Section 6.7. Formulations 22

Section 6.8. Dissolution 22

Section 6.9. Assay 24

Section 6.10. Comments 24

Section 6.11. Recommendation 24

Section 7. Integrated review of effectiveness 25

Section 7.1. Mechanism of action 25
Section 7.1.1. Single-dose studies 25
Section 7.1.1.1. Mixed etiology 25
Section 7.1.1.2. Psychogenic etiology 25
Section 7.1.1.3. Diabetes 26
Section 7.1.1.4. Spinal cord injury 26
Section 7.1.2. Multiple-dose studies 26
Section 7.1.2.1. Psychogenic etiology 26
Section 7.1.3. Effects by etiology of erectile dysfunction 26
Section 7.1.4. Time course of effects after a dose 26
Section 7.1.5. Time course of effects with repetitive dosing 26
Section 7.1.6. Relationship between dose and erectile function 26
Section 7.1.7. Relationship between plasma levels and erectile function 27

Section 7.2. Effects on sexual performance 27
Section 7.2.1. Methods of assessment 27
Section 7.2.1.1. Primary 27
Section 7.2.1.2. Supportive 27
Section 7.2.2. Dose dependence 27
Section 7.2.2.1. Common characteristics of fixed-dose studies 27
Section 7.2.2.2. Fixed-dose studies assessed by IIEF 28
Section 7.2.2.2.1. Analyses of sexual performance by IIEF 28
Section 7.2.2.2.2. Analyses of other IIEF questions 30
Section 7.2.2.2.3. Analyses of event logs 31
Section 7.2.3. Titration studies 32
Section 7.2.3.1. Common characteristics of titration studies 32
Section 7.2.3.2. Titration studies assessed by IIEF 32
Section 7.2.3.2.1. Analyses of sexual performance by IIEF 33
Section 7.2.3.2.2. Analyses of other IIEF questions 34
Section 7.2.3.2.3. Analyses of event logs 35

Section 7.3. Summary of key effectiveness findings 36
Section 7.3.1. Mechanism of action 36
Section 7.3.2. Dose-dependent effects 36
Section 7.3.3. Time course of effects 36
Section 7.3.3.1. Time course after a dose 36
Section 7.3.3.2. Time course with repeated dosing 37
Section 7.3.4. Effectiveness in sub-groups 37
Section 7.3.4.1. Non-specific organic etiology 37
Section 7.3.4.2. Psychogenic etiology 37
Section 7.3.4.3. Diabetes 38

Section 7.3.4.4. Spinal cord trauma 38
Section 7.3.4.5. Blacks 39
Section 7.3.4.6. Elderly 39

Section 8. Integrated review of safety 40

Section 8.1. Methodology 40
Section 8.1.1. Deaths 40
Section 8.1.2. Serious adverse events 40
Section 8.1.3. Withdrawals and other significant adverse events 40
Section 8.1.3.1. Overall profile of withdrawals 40
Section 8.1.3.2. Adverse events associated with withdrawal 40
Section 8.1.3.3. Other significant adverse events 40
Section 8.1.4. Other search strategies 40
Section 8.1.5. Adverse event incidence 40
Section 8.1.5.1. Approach to eliciting adverse events in the development program 40
Section 8.1.5.2. Appropriateness of adverse event categorization and preferred terms 40
Section 8.1.5.3. Identifying common and drug-related adverse events 40
Section 8.1.5.4. Additional analyses 40
Section 8.1.6. Laboratory findings 40
Section 8.1.6.1. Extent of laboratory testing 40
Section 8.1.6.2. Selection of studies and analyses for drug-control comparisons 40
Section 8.1.6.3. Standard analyses 41
Section 8.1.6.3.1. Analyses focussed on central tendency and outliers 41
Section 8.1.6.3.2. Withdrawals for laboratory abnormalities 41
Section 8.1.7. Vital signs 41
Section 8.1.8. ECGs 41
Section 8.1.9. Special studies 41
Section 8.1.10. Withdrawal phenomena 41
Section 8.1.11. Abuse potential 41
Section 8.1.12. Human reproduction data 41
Section 8.1.13. Overdose experience 41

Section 8.2. Safety results 41
Section 8.2.1. Deaths 41
Section 8.2.2. Withdrawals 42
Section 8.2.2.1. Withdrawals for any cause 42
Section 8.2.2.1.1. Withdrawals from placebo-controlled studies 42
Section 8.2.2.1.2. Withdrawals from open-label extensions 43
Section 8.2.2.2. Withdrawals for adverse events 43
Section 8.2.2.2.1. Withdrawals from placebo-controlled studies 43
Section 8.2.2.2.2. Withdrawals from open-label extensions 47
Section 8.2.3. Common adverse events 48
Section 8.2.3.1. Relationship to dose 48
Section 8.2.3.2. Overall incidence 49
Section 8.2.4. Laboratory data 50
Section 8.2.4.1. Hepatic function 50
Section 8.2.4.2. Renal function 50
Section 8.2.4.3. Electrolytes, hematology, etc. 50
Section 8.2.4.4. Vital signs 51
Section 8.2.4.5. ECG 52
Section 8.2.5. Pharmacologic basis for safety issues 53
Section 8.2.5.1. Vital signs 54
Section 8.2.5.2. Hemorrhage 55
Section 8.2.5.3. Weakness 55

Section 8.2.5.4. Decreased gastrointestinal motility 55
Section 8.2.5.5. Vision abnormalities 55
Section 8.3. Summary of key safety findings 55
Section 9. Labeling review 57
Section 10. Summary and recommendations 69
Section 10.1. Chemistry 69
Section 10.2. Pharmacology and toxicology 69
Section 10.3. Biopharmaceutics 69
Section 10.4. Effectiveness 69
Section 10.5. Safety 69
Section 10.6. Recommendation 70
Section 10.7. Comments on label 70
Appendix A. Study reports 71
Appendix A1. In vitro metabolism studies 71
Appendix A1.1. Report DM2: In vitro metabolism of UK-92480 in hepatic microsomes from rat, dog, rabbit, and man. 71
Appendix A1.1.1. Methods 71
Appendix A1.1.2. Results 71
Appendix A1.2. Report DM3: In vitro metabolism of UK-92480 in human liver microsomes enzymology of UK-103,320 formation. 71
Appendix A1.2.1. Source documents 71
Appendix A1.2.2. Objectives 71
Appendix A1.2.3. Methods 71
Appendix A1.2.4. Results 72
Appendix A1.2.5. Conclusion 73
Appendix A1.3. Report DM4: In vitro inhibition studies on UK-92480 in human liver microsomes. 73
Appendix A1.3.1. Source documents 73
Appendix A1.3.2. Objectives 73
Appendix A1.3.3. Results 73
Appendix A1.3.4. Conclusion 73
Appendix A1.4. Report DM5: In vitro metabolism and P450 inhibition studies of UK-103,320 in human liver microsomes. 73
Appendix A1.4.1. Source documents 73
Appendix A1.4.2. Objectives 73
Appendix A1.4.3. Methods 74
Appendix A1.4.4. Results 74
Appendix A1.5. Report DM34: In vitro interaction between UK-92480 and the CYP3A4 substrates terfenadine and testosterone in human liver microsomes. 74
Appendix A1.5.1. Source documents 74
Appendix A1.5.2. Objectives 74
Appendix A1.5.3. Results 74
Appendix A2. Population pharmacokinetic and pharmacodynamic analysis of sildenafil phase III data 75

Appendix A2.1. Methods 75
Appendix A2.1.1. Data collection 75
Appendix A2.1.2. Pharmacokinetic modeling 75
Appendix A2.1.3. Pharmacokinetic-pharmacodynamic modeling 75

Appendix A2.2. Results 76
Appendix A2.2.1. Sildenafil pharmacokinetics 77
Appendix A2.2.2. UK-103,320 pharmacokinetics 79
Appendix A2.2.3. Pharmacodynamics 81
Appendix A2.2.4. Adverse events 84

Appendix A2.3. Summary 85

Appendix A3. Development and validation of the primary efficacy instrument (International Index of Erectile Function; IIEF). 87

Appendix A3.1. Source documents 87

Appendix A3.2. IIEF development 87

Appendix A3.3. IIEF validation studies 87

Appendix A4. Study 148-001: Phase I single dose, open study of the clinical pharmacology of sildenafil in elderly and young healthy male volunteers. 89

Appendix A4.1. Source documents 89

Appendix A4.2. Investigators 89

Appendix A4.3. Study dates 89

Appendix A4.4. Study design 89
Appendix A4.4.1. Objectives 89
Appendix A4.4.2. Formulation 89
Appendix A4.4.3. Population 89
Appendix A4.4.4. Procedures 89
Appendix A4.4.5. Assay 89
Appendix A4.4.6. Analysis 89
Appendix A4.4.7. Safety 89

Appendix A4.5. Results 89
Appendix A4.5.1. Conduct 89
Appendix A4.5.2. Pharmacokinetics 89
Appendix A4.5.3. Safety 91

Appendix A4.6. Summary 91

Appendix A5. Study 148-002: Phase I open study to assess the potential of cimetidine to alter the pharmacokinetics of sildenafil (UK-92,480) in normal, healthy male subjects. 92

Appendix A5.1. Source documents 92

Appendix A5.2. Investigators 92

Appendix A5.3. Study dates 92

Appendix A5.4. Study design 92

Appendix A5.5. Results 93
Appendix A5.5.1. Conduct 93
Appendix A5.5.2. Pharmacokinetics 93
Appendix A5.5.3. Safety 93

Appendix A5.6. Summary **93**

Appendix A6. Study 148-003: Phase I open study to assess the effect of concomitant antacid administration on the absorption of sildenafil (UK-92,480) in normal, healthy male subjects **94**

Appendix A6.1. Source documents **94**

Appendix A6.2. Investigators **94**

Appendix A6.3. Study dates **94**

Appendix A6.4. Study design **94**

Appendix A6.5. Results **94**
Appendix A6.5.1. Conduct **94**
Appendix A6.5.2. Pharmacokinetics **95**
Appendix A6.5.3. Safety **95**

Appendix A6.6. Summary **95**

Appendix A7. Study 148-004: Phase I investigator-blind, placebo-controlled, evaluation of safety, toleration, and pharmacokinetics of sildenafil following escalating single oral doses in healthy male volunteers **96**

Appendix A7.1. Source documents **96**

Appendix A7.2. Investigators **96**

Appendix A7.3. Study dates **96**

Appendix A7.4. Study design **96**

Appendix A7.5. Results **96**
Appendix A7.5.1. Conduct **96**
Appendix A7.5.2. Pharmacokinetics **96**
Appendix A7.5.3. Safety **98**

Appendix A7.6. Summary **98**

Appendix A8. Study 148-101/101B: A randomised, double-blind, placebo controlled, parallel-group, fixed-dose, multicentre, long-term dose-response study to assess the efficacy and safety of sildenafil (UK-92,480) administered prior to sexual activity to male patients with erectile dysfunction **99**

Appendix A8.1. Source documents **99**

Appendix A8.2. Investigators **99**

Appendix A8.3. Study dates **99**

Appendix A8.4. Study design **99**

Appendix A8.5. Results **100**
Appendix A8.5.1. Conduct **100**
Appendix A8.5.2. Effectiveness **100**
Appendix A8.5.3. Safety **101**

Appendix A8.6. Summary **101**

Appendix A9. Study 148-101C: An open, non-comparative study to assess the long-term safety of sildenafil in patients with erectile dysfunction. **102**

Appendix A9.1. Source documents **102**

Appendix A9.2. Investigators **102**

Appendix A9.3. Study dates 102

Appendix A9.4. Study design 102

Appendix A9.5. Results 102
Appendix A9.5.1. Conduct 102
Appendix A9.5.2. Effectiveness 103
Appendix A9.5.3. Safety 103

Appendix A9.6. Summary 103

Appendix A10. Study 148-102: A double-blind, randomized, placebo-controlled, parallel group, fixed-dose, multicenter study to assess the efficacy and safety of UK-92,480 administered over six months to male patients with erectile dysfunction. 104

Appendix A10.1. Source documents 104

Appendix A10.2. Investigators 104

Appendix A10.3. Study dates 104

Appendix A10.4. Study design 104

Appendix A10.5. Results 105
Appendix A10.5.1. Conduct 105
Appendix A10.5.2. Effectiveness 107
Appendix A10.5.3. Safety 110
Appendix A10.5.4. Long-term 110

Appendix A10.6. Summary 110

Appendix A11. Study 148-103: A double-blind, randomized, placebo-controlled, parallel group, multicenter, flexible dose escalation study to assess the efficacy and safety of sildenafil administered as required to male patients with erectile dysfunction. 111

Appendix A11.1. Source documents 111

Appendix A11.2. Investigators 111

Appendix A11.3. Study dates 111

Appendix A11.4. Study design 111

Appendix A11.5. Results 112
Appendix A11.5.1. Conduct 112
Appendix A11.5.2. Effectiveness 114
Appendix A11.5.3. Safety 116
Appendix A11.5.4. Long-term 116

Appendix A11.6. Summary 117

Appendix A12. Study 148-104: A double-blind, randomized, placebo-controlled, parallel group, multicenter, flexible dose escalation study to assess the efficacy and safety of sildenafil administered as required to male diabetic patients with erectile dysfunction. 118

Appendix A12.1. Source documents 118

Appendix A12.2. Investigators 118

Appendix A12.3. Study dates 118

Appendix A12.4. Study design 118

Appendix A12.5. Results 119

Appendix A12.5.1. Conduct 119
Appendix A12.5.2. Effectiveness 121
Appendix A12.5.3. Safety 122
Appendix A12.5.4. Long-term 122

Appendix A12.6. Summary 123

Appendix A13. Study 148-105: A double-blind, randomised, placebo controlled, four-way crossover study to investigate the efficacy, safety and toleration of single oral dose of sildenafil (25, 50, and 100 mg) in patients with male erectile dysfunction. 124

Appendix A13.1. Source documents 124

Appendix A13.2. Investigators 124

Appendix A13.3. Study dates 124

Appendix A13.4. Study design 124

Appendix A13.5. Results 124
Appendix A13.5.1. Conduct 124
Appendix A13.5.2. Effectiveness 125
Appendix A13.5.3. Pharmacokinetics 125
Appendix A13.5.4. Safety 125

Appendix A13.6. Summary 125

Appendix A14. Study 148-106: A double-blind, randomised, placebo controlled, parallel group, multicentre, fixed-dose study to assess the efficacy and safety of sildenafil administered as required to male subjects with erectile dysfunction. 126

Appendix A14.1. Source documents 126

Appendix A14.2. Investigators 126

Appendix A14.3. Study dates 126

Appendix A14.4. Study design 126

Appendix A14.5. Results 127
Appendix A14.5.1. Conduct 127
Appendix A14.5.2. Effectiveness 128
Appendix A14.5.3. Safety 130

Appendix A14.6. Summary 130

Appendix A15. Study 148-203: A single blind, four way crossover study to investigate the pharmacokinetics of and assess the safety and tolerance of UK-92480 after administration of escalating intravenous doses in the fasted state. 131

Appendix A15.1. Source documents 131

Appendix A15.2. Investigators 131

Appendix A15.3. Study dates 131

Appendix A15.4. Study design 131
Appendix A15.4.1. Objectives 131
Appendix A15.4.2. Formulation 131
Appendix A15.4.3. Population 131
Appendix A15.4.4. Procedures 131
Appendix A15.4.5. Assay 131

Appendix A15.4.6. Analysis 131
Appendix A15.4.7. Safety 131

Appendix A15.5. Results 131
Appendix A15.5.1. Pharmacokinetics 131

Appendix A15.6. Summary 132

Appendix A16. Study 148-204: An open study in normal volunteers to investigate the effects of an escalating brachial artery infusion of UK-92,480 on forearm blood flow and forearm venous compliance. 133

Appendix A16.1. Source documents 133

Appendix A16.2. Investigators 133

Appendix A16.3. Study dates 133

Appendix A16.4. Study design 133

Appendix A16.5. Results 133
Appendix A16.5.1. Conduct 133
Appendix A16.5.2. Pharmacokinetics 133
Appendix A16.5.3. Pharmacodynamics 133
Appendix A16.5.4. Safety 133

Appendix A16.6. Summary 133

Appendix A17. Study 148-206: A single blind, two way crossover, placebo controlled pilot study to investigate the effects of UK-92,480 (sildenafil) on platelet function in normal male volunteers. 134

Appendix A17.1. Source documents 134

Appendix A17.2. Investigators 134

Appendix A17.3. Study dates 134

Appendix A17.4. Study design 134

Appendix A17.5. Results 134
Appendix A17.5.1. Conduct 134
Appendix A17.5.2. Pharmacokinetics 134
Appendix A17.5.3. Pharmacodynamics 134
Appendix A17.5.4. Safety 134

Appendix A17.6. Summary 134

Appendix A18. Study 148-207: A double blind, placebo controlled, single dose study followed by a double blind, placebo controlled 10-day multiple dose study to investigate the pharmacokinetics, platelet effects, safety and toleration of UK-92,480 (sildenafil) in healthy male volunteers. 135

Appendix A18.1. Source documents 135

Appendix A18.2. Investigators 135

Appendix A18.3. Study dates 135

Appendix A18.4. Study design 135
Appendix A18.4.1. Objectives 135
Appendix A18.4.2. Formulation 135
Appendix A18.4.3. Population 135
Appendix A18.4.4. Procedures 135
Appendix A18.4.5. Assay 135
Appendix A18.4.6. Analysis 135

Appendix A18.4.7. Safety 136

Appendix A18.5. Results 136
Appendix A18.5.1. Conduct 136
Appendix A18.5.2. Pharmacokinetics 136
Appendix A18.5.3. Pharmacodynamics 137
Appendix A18.5.4. Safety 137

Appendix A18.6. Summary 137

Appendix A19. Study 148-208: An open randomised, two way crossover study to investigate the pharmacokinetics of UK-92480 after oral administration and IV administration in the fasted state. 139

Appendix A19.1. Source documents 139

Appendix A19.2. Investigators 139

Appendix A19.3. Study dates 139

Appendix A19.4. Study design 139
Appendix A19.4.1. Objectives 139
Appendix A19.4.2. Formulation 139
Appendix A19.4.3. Population 139
Appendix A19.4.4. Procedures 139
Appendix A19.4.5. Assay 139
Appendix A19.4.6. Analysis 139
Appendix A19.4.7. Safety 139

Appendix A19.5. Results 139
Appendix A19.5.1. Pharmacokinetics 139

Appendix A19.6. Summary 140

Appendix A20. Study 148-209: A double blind, randomised, placebo controlled, two-way crossover study to examine the effects of 25mg tid UK-92,480, administered as capsules, on the haemodynamic responses to glyceryl trinitrate in normal volunteers. 141

Appendix A20.1. Source documents 141

Appendix A20.2. Investigators 141

Appendix A20.3. Study dates 141

Appendix A20.4. Study design 141

Appendix A20.5. Results 141
Appendix A20.5.1. Conduct 141
Appendix A20.5.2. Pharmacokinetics 141
Appendix A20.5.3. Pharmacodynamics 141
Appendix A20.5.4. Safety 141

Appendix A20.6. Summary 141

Appendix A21. Study 148-214: An open, parallel group study to determine the effects of impaired renal function on the pharmacokinetics, safety and toleration of sildenafil administered as a single 50 mg capsule dose. 142

Appendix A21.1. Source documents 142

Appendix A21.2. Investigators 142

Appendix A21.3. Study dates 142

Appendix A21.4. Study design 142

Appendix A21.4.1. Objectives 142
Appendix A21.4.2. Formulation 142
Appendix A21.4.3. Population 142
Appendix A21.4.4. Procedures 142
Appendix A21.4.5. Assay 142
Appendix A21.4.6. Analysis 142
Appendix A21.4.7. Safety 142

Appendix A21.5. Results 142
Appendix A21.5.1. Pharmacokinetics 142
Appendix A21.5.2. Safety 144

Appendix A21.6. Summary 144

Appendix A22. Study 148-215: An open, parallel group study to investigate the absorption, metabolism and excretion of a single oral and a single intravenous dose of radiolabeled [^{14}C]-UK-92,480. 145

Appendix A22.1. Source documents 145

Appendix A22.2. Investigators 145

Appendix A22.3. Study dates 145

Appendix A22.4. Study design 145
Appendix A22.4.1. Objectives 145
Appendix A22.4.2. Formulation 145
Appendix A22.4.3. Population 145
Appendix A22.4.4. Procedures 145
Appendix A22.4.5. Assay 145
Appendix A22.4.6. Analysis 146
Appendix A22.4.7. Safety 146

Appendix A22.5. Results 146
Appendix A22.5.1. Pharmacokinetics 146

Appendix A22.6. Summary 149

Appendix A23. Study 148-216: An open study to investigate the effects of a single dose of UK-92,480 (50mg) on bleeding time, followed by a double-blind, placebo-controlled, two-way crossover study to investigate the effects of a single dose of UK-92,480 (50mg) on aspirin-induced prolongation of bleeding time in healthy male volunteers. 150

Appendix A23.1. Source documents 150

Appendix A23.2. Investigators 150

Appendix A23.3. Study dates 150

Appendix A23.4. Study design 150

Appendix A23.5. Results 150
Appendix A23.5.1. Conduct 150
Appendix A23.5.2. Pharmacodynamics 150
Appendix A23.5.3. Safety 150

Appendix A23.6. Summary 150

Appendix A24. Study 148-217: A double blind, randomised, placebo controlled, three way crossover study to investigate the haemodynamic and pharmacokinetic interactions of sildenafil and alcohol in healthy male volunteers. 151

Appendix A24.1. Source documents 151

Appendix A24.2. Investigators 151

Appendix A24.3. Study dates 151

Appendix A24.4. Study design 151
Appendix A24.4.1. Objectives 151
Appendix A24.4.2. Formulation 151
Appendix A24.4.3. Population 151
Appendix A24.4.4. Procedures 151
Appendix A24.4.5. Assay 151
Appendix A24.4.6. Analysis 151
Appendix A24.4.7. Safety 151

Appendix A24.5. Results 151
Appendix A24.5.1. Pharmacokinetics 151
Appendix A24.5.2. Safety 152

Appendix A24.6. Summary 152

Appendix A25. Study 148-218: A double blind, randomised, placebo controlled, two-way crossover study to investigate any pharmacokinetic or pharmacodynamic interaction between orally administered UK-92,480 and tolbutamide in healthy male volunteers. 153

Appendix A25.1. Source documents 153

Appendix A25.2. Investigators 153

Appendix A25.3. Study dates 153

Appendix A25.4. Study design 153
Appendix A25.4.1. Objectives 153
Appendix A25.4.2. Formulation 153
Appendix A25.4.3. Population 153
Appendix A25.4.4. Procedures 153
Appendix A25.4.5. Assay 153
Appendix A25.4.6. Analysis 153
Appendix A25.4.7. Safety 153

Appendix A25.5. Results 153
Appendix A25.5.1. Conduct 153
Appendix A25.5.2. Pharmacokinetics 154
Appendix A25.5.3. Safety 154

Appendix A25.6. Summary 154

Appendix A26. Study 148-219: A double-blind, randomised, placebo-controlled, two-way crossover study to assess the potential interaction between orally administered UK-92,480 (sildenafil) and warfarin in healthy male volunteers. 155

Appendix A26.1. Source documents 155

Appendix A26.2. Investigators 155

Appendix A26.3. Study dates 155

Appendix A26.4. Study design 155
Appendix A26.4.1. Objectives 155
Appendix A26.4.2. Formulation 155
Appendix A26.4.3. Population 155

Appendix A26.4.4. Procedures 155
Appendix A26.4.5. Assay 155
Appendix A26.4.6. Safety 155

Appendix A26.5. Results 155
Appendix A26.5.1. Conduct 155
Appendix A26.5.2. Pharmacodynamics 155

Appendix A26.6. Summary 156

Appendix A27. Study 148-221: An open, single dose study to compare the pharmacokinetics, safety and toleration of a single oral dose of sildenafil in patients with chronic stable hepatic cirrhosis to healthy subjects with normal hepatic function. 157

Appendix A27.1. Source documents 157

Appendix A27.2. Investigators 157

Appendix A27.3. Study dates 157

Appendix A27.4. Study design 157
Appendix A27.4.1. Objectives 157
Appendix A27.4.2. Formulation 157
Appendix A27.4.3. Population 157
Appendix A27.4.4. Procedures 157
Appendix A27.4.5. Assay 157
Appendix A27.4.6. Analysis 157
Appendix A27.4.7. Safety 157

Appendix A27.5. Results 157
Appendix A27.5.1. Pharmacokinetics 157

Appendix A27.6. Summary 158

Appendix A28. Study 148-222: Single blind, placebo controlled, parallel group study to investigate the effects of a single oral dose of sildenafil (UK-92,480) (100mg) and isosorbide dinitrate (20mg) on aspirin-induced prolongation of bleeding time in healthy male volunteers. 159

Appendix A28.1. Source documents 159

Appendix A28.2. Investigators 159

Appendix A28.3. Study dates 159

Appendix A28.4. Study design 159

Appendix A28.5. Results 159
Appendix A28.5.1. Conduct 159
Appendix A28.5.2. Pharmacokinetics 159
Appendix A28.5.3. Pharmacodynamics 159
Appendix A28.5.4. Safety 159

Appendix A28.6. Summary 159

Appendix A29. Study 148-223: A double-blind, randomised, placebo controlled, four period crossover study to assess the effect of orally administered sildenafil (50, 100 and 200mg) on visual function in healthy male volunteers. 160

Appendix A29.1. Source documents 160

Appendix A29.2. Investigators 160

Appendix A29.3. Study dates **160**

Appendix A29.4. Study design **160**

Appendix A29.5. Results **160**
Appendix A29.5.1. Conduct **160**
Appendix A29.5.2. Pharmacokinetics **160**
Appendix A29.5.3. Pharmacodynamics **160**
Appendix A29.5.4. Safety **161**

Appendix A29.6. Summary **161**

Appendix A30. Study 148-225: A double-blind, placebo controlled, two way crossover study to investigate the effects of a single dose of sildenafil (100 mg) on blood pressure in subjects with essential hypertension being treated with amlodipine. **162**

Appendix A30.1. Source documents **162**

Appendix A30.2. Investigators **162**

Appendix A30.3. Study dates **162**

Appendix A30.4. Study design **162**

Appendix A30.5. Results **162**
Appendix A30.5.1. Conduct **162**
Appendix A30.5.2. Pharmacokinetics **162**
Appendix A30.5.3. Pharmacodynamics **162**
Appendix A30.5.4. Safety **162**

Appendix A30.6. Summary **162**

Appendix A31. Study 148-226: An open, randomised, single oral dose, three way crossover bioequivalence study to determine the pharmacokinetics of sildenafil in healthy male volunteers following administration of 100mg as capsules and tablets in the fasted state. **163**

Appendix A31.1. Source documents **163**

Appendix A31.2. Investigators **163**

Appendix A31.3. Study dates **163**

Appendix A31.4. Study design **163**
Appendix A31.4.1. Objectives **163**
Appendix A31.4.2. Formulation **163**
Appendix A31.4.3. Population **163**
Appendix A31.4.4. Procedures **163**
Appendix A31.4.5. Assay **163**
Appendix A31.4.6. Analysis **163**
Appendix A31.4.7. Safety **163**

Appendix A31.5. Results **163**
Appendix A31.5.1. Conduct **163**
Appendix A31.5.2. Pharmacokinetics **163**
Appendix A31.5.3. Safety **164**

Appendix A31.6. Summary **164**

Appendix A32. Study 148-227: An open randomised, single oral dose, two way crossover study to determine the pharmacokinetics of sildenafil in healthy male volunteers following administration of 100 mg as commercial tablets in the fed and fasted state **165**

Appendix A32.1. Source documents 165

Appendix A32.2. Investigators 165

Appendix A32.3. Study dates 165

Appendix A32.4. Study design 165
Appendix A32.4.1. Objectives 165
Appendix A32.4.2. Formulation 165
Appendix A32.4.3. Population 165
Appendix A32.4.4. Procedures 165
Appendix A32.4.5. Assay 165
Appendix A32.4.6. Analysis 165
Appendix A32.4.7. Safety 165

Appendix A32.5. Results 165
Appendix A32.5.1. Conduct 165
Appendix A32.5.2. Pharmacokinetics 165
Appendix A32.5.3. Safety 166

Appendix A32.6. Summary 166

Appendix A33. Study 148-228: An open, randomised, single oral dose, four way crossover study to determine the dose proportionality of the pharmacokinetics of sildenafil in healthy male volunteers over the dose range 25mg to 200mg 167

Appendix A33.1. Source documents 167

Appendix A33.2. Investigators 167

Appendix A33.3. Study dates 167

Appendix A33.4. Study design 167
Appendix A33.4.1. Objectives 167
Appendix A33.4.2. Formulation 167
Appendix A33.4.3. Population 167
Appendix A33.4.4. Procedures 167
Appendix A33.4.5. Assay 167
Appendix A33.4.6. Analysis 167
Appendix A33.4.7. Safety 167

Appendix A33.5. Results 167
Appendix A33.5.1. Conduct 167
Appendix A33.5.2. Pharmacokinetics 167
Appendix A33.5.3. Safety 168

Appendix A33.6. Summary 168

Appendix A34. Study 148-229: A double-blind, randomised, single oral dose, four period, two-way crossover pilot study to investigate the acute effects of sildenafil on sperm motility 170

Appendix A34.1. Source documents 170

Appendix A34.2. Investigators 170

Appendix A34.3. Study dates 170

Appendix A34.4. Study design 170
Appendix A34.4.1. Objectives 170
Appendix A34.4.2. Formulation 170
Appendix A34.4.3. Population 170

Appendix A34.4.4. Procedures 170
Appendix A34.4.5. Assay 170
Appendix A34.4.6. Analysis 170

Appendix A34.5. Results 171
Appendix A34.5.1. Conduct 171
Appendix A34.5.2. Pharmacokinetics 171
Appendix A34.5.3. Pharmacodynamics 172
Appendix A34.5.4. Safety 172

Appendix A34.6. Summary 172

Appendix A35. Study 148-230: A double blind, placebo controlled, randomised, two way crossover study to investigate the effects of a single dose of sildenafil (50mg) in patients with stable angina taking isosorbide mononitrate oral therapy. 173

Appendix A35.1. Source documents 173

Appendix A35.2. Investigators 173

Appendix A35.3. Study dates 173

Appendix A35.4. Study design 173

Appendix A35.5. Results 173
Appendix A35.5.1. Conduct 173
Appendix A35.5.2. Pharmacodynamics 173
Appendix A35.5.3. Safety 174

Appendix A35.6. Summary 174

Appendix A36. Study 148-231: A double blind, placebo controlled, randomised, two way crossover study to investigate the effects of a single dose of sildenafil (50mg) in patients with stable angina taking sublingual glyceryl trinitrate (GTN) therapy. 175

Appendix A36.1. Source documents 175

Appendix A36.2. Investigators 175

Appendix A36.3. Study dates 175

Appendix A36.4. Study design 175

Appendix A36.5. Results 175
Appendix A36.5.1. Conduct 175
Appendix A36.5.2. Pharmacodynamics 175
Appendix A36.5.3. Safety 176

Appendix A36.6. Summary 176

Appendix A37. Study 148-232: A randomised, double-blind, placebo-controlled, crossover pilot study to investigate the effects of a single oral tablet dose of sildenafil (200mg) on visual function (electroretinogram, photostress, visual field and colour discrimination tests) in healthy male volunteers and patients with diabetic retinopathy 177

Appendix A37.1. Source documents 177

Appendix A37.2. Investigators 177

Appendix A37.3. Study dates 177

Appendix A37.4. Study design 177

Appendix A37.5. Results 177
Appendix A37.5.1. Conduct 177
Appendix A37.5.2. Pharmacokinetics 177
Appendix A37.5.3. Pharmacodynamics 177
Appendix A37.5.4. Safety 178

Appendix A37.6. Summary 178

Appendix A38. Study 148-234: An open, randomised, placebo controlled, parallel group study to investigate the effects of multiple doses of erythromycin on the pharmacokinetics of a single 100mg dose of sildenafil 179

Appendix A38.1. Source documents 179

Appendix A38.2. Investigators 179

Appendix A38.3. Study dates 179

Appendix A38.4. Study design 179
Appendix A38.4.1. Objectives 179
Appendix A38.4.2. Formulation 179
Appendix A38.4.3. Population 179
Appendix A38.4.4. Procedures 179
Appendix A38.4.5. Assay 179
Appendix A38.4.6. Analysis 179
Appendix A38.4.7. Safety 179

Appendix A38.5. Results 179
Appendix A38.5.1. Conduct 179
Appendix A38.5.2. Pharmacokinetics 179
Appendix A38.5.3. Safety 180

Appendix A38.6. Summary 180

Appendix A39. Study 148-301: An open single intravenous dose study of the haemodynamic effects of UK-92,480 (sildenafil) in patients with stable ischaemic heart disease. 181

Appendix A39.1. Source documents 181

Appendix A39.2. Investigators 181

Appendix A39.3. Study dates 181

Appendix A39.4. Study design 181

Appendix A39.5. Results 181
Appendix A39.5.1. Conduct 181
Appendix A39.5.2. Pharmacokinetics 181
Appendix A39.5.3. Pharmacodynamics 181
Appendix A39.5.4. Safety 181

Appendix A39.6. Summary 182

Appendix A40. Study 148-350: A double blind, randomised, placebo controlled, two way crossover pilot study to investigate the efficacy and safety of UK-92,480 (sildenafil, 25mg tid for 7 days) in patients with impotence.. 183

Appendix A40.1. Source documents 183

Appendix A40.2. Investigators 183

Appendix A40.3. Study dates 183

Appendix A40.4. Study design 183

Appendix A40.5. Results 183
Appendix A40.5.1. Conduct 183
Appendix A40.5.2. Pharmacodynamics 183
Appendix A40.5.3. Safety 183

Appendix A40.6. Summary 183

Appendix A41. Study 148-351: A double blind, randomised, placebo controlled, four way crossover study followed by a double blind, randomised, placebo controlled, two way crossover study to investigate the efficacy of single doses of UK-92,480 (sildenafil) in patients with erectile dysfunction with no established organic cause. 184

Appendix A41.1. Source documents 184

Appendix A41.2. Investigators 184

Appendix A41.3. Study dates 184

Appendix A41.4. Study design 184

Appendix A41.5. Results 184
Appendix A41.5.1. Conduct 184
Appendix A41.5.2. Pharmacokinetics 184
Appendix A41.5.3. Pharmacodynamics 184
Appendix A41.5.4. Safety 184

Appendix A41.6. Summary 185

Appendix A42. Study 148-353: A randomised, double-blind, placebo controlled, parallel-group, multicentre, dose-response study to assess the efficacy and safety of sildenafil (UK-92,480) administered once daily for 28 days to patients with erectile dysfunction. 186

Appendix A42.1. Source documents 186

Appendix A42.2. Investigators 186

Appendix A42.3. Study dates 186

Appendix A42.4. Study design 186

Appendix A42.5. Results 186
Appendix A42.5.1. Conduct 186
Appendix A42.5.2. Effectiveness 187
Appendix A42.5.3. Safety 188

Appendix A42.6. Summary 188

Appendix A43. Study 148-354A: An open, non-comparative study to assess the efficacy and safety of UK-92,480 (sildenafil) taken over a 52-week period by patients with erectile dysfunction 189

Appendix A43.1. Source documents 189

Appendix A43.2. Investigators 189

Appendix A43.3. Study dates 189

Appendix A43.4. Study design 189

Appendix A43.5. Results 189
Appendix A43.5.1. Conduct 189
Appendix A43.5.2. Effectiveness 190

Appendix A43.5.3. Safety **190**
Appendix A43.5.4. Long-term **190**

Appendix A43.6. Summary **190**

Appendix A44. Study 148-355: A double blind, randomised, placebo controlled, two way crossover study to investigate the efficacy of single doses of sildenafil (UK-92,480) (taken when required over a 28 day period) in patients with erectile dysfunction with no established organic cause. **191**

Appendix A44.1. Source documents **191**

Appendix A44.2. Investigators **191**

Appendix A44.3. Study dates **191**

Appendix A44.4. Study design **191**

Appendix A44.5. Results **191**
Appendix A44.5.1. Conduct **191**
Appendix A44.5.2. Effectiveness **192**
Appendix A44.5.3. Safety **192**
Appendix A44.5.4. Long-term **192**

Appendix A44.6. Summary **192**

Appendix A45. Study 148-356: A multi-centre study consisting of a 16-week open, dose-escalation phase followed by an 8-week randomised, double-blind, placebo controlled phase to assess the efficacy and safety of oral doses of UK-92,480 (sildenafil) taken as required by patients with erectile dysfunction. **193**

Appendix A45.1. Source documents **193**

Appendix A45.2. Investigators **193**

Appendix A45.3. Study dates **193**

Appendix A45.4. Study design **193**

Appendix A45.5. Results **193**
Appendix A45.5.1. Conduct **193**
Appendix A45.5.2. Effectiveness **194**
Appendix A45.5.3. Safety **194**
Appendix A45.5.4. Long-term **194**

Appendix A45.6. Summary **194**

Appendix A46. Study 148-357: A multi-centre, double blind, randomised, placebo controlled, three way crossover study to investigate the efficacy of single oral doses of sildenafil (UK-92,480) in diabetic patients with penile erectile dysfunction. **195**

Appendix A46.1. Source documents **195**

Appendix A46.2. Investigators **195**

Appendix A46.3. Study dates **195**

Appendix A46.4. Study design **195**

Appendix A46.5. Results **195**
Appendix A46.5.1. Conduct **195**
Appendix A46.5.2. Effectiveness **195**
Appendix A46.5.3. Safety **196**
Appendix A46.5.4. Long-term **196**

Appendix A46.6. Summary **196**

Appendix A47. Study 148-358: A two stage, double blind, placebo-controlled study to assess the efficacy and safety of oral doses of sildenafil (UK-92,480) in spinal cord injury patients with erectile dysfunction. **197**

Appendix A47.1. Source documents **197**

Appendix A47.2. Investigators **197**

Appendix A47.3. Study dates **197**

Appendix A47.4. Study design **197**

Appendix A47.5. Results **197**
Appendix A47.5.1. Conduct **197**
Appendix A47.5.2. Effectiveness **198**
Appendix A47.5.3. Safety **198**
Appendix A47.5.4. Long-term **198**

Appendix A47.6. Summary **198**

Appendix A48. Study 148-359: A 12 week, double blind, placebo controlled, parallel group, multicentre study to evaluate a new sexual function questionnaire in the assessment of the efficacy of sildenafil (UK-92,480) in patients with erectile dysfunction. **199**

Appendix A48.1. Source documents **199**

Appendix A48.2. Investigators **199**

Appendix A48.3. Study dates **199**

Appendix A48.4. Study design **199**

Appendix A48.5. Results **199**
Appendix A48.5.1. Conduct **199**
Appendix A48.5.2. Effectiveness **200**
Appendix A48.5.3. Safety **200**
Appendix A48.5.4. Long-term **200**

Appendix A48.6. Summary **200**

Appendix A49. Study 148-360: A double-blind, randomised, placebo controlled, two-way crossover study to investigate the onset of action of single oral doses of UK-92,480 (sildenafil) 50mg in patients with penile erectile dysfunction without an established organic cause. **201**

Appendix A49.1. Source documents **201**

Appendix A49.2. Investigators **201**

Appendix A49.3. Study dates **201**

Appendix A49.4. Study design **201**

Appendix A49.5. Results **201**
Appendix A49.5.1. Conduct **201**
Appendix A49.5.2. Pharmacokinetics **201**
Appendix A49.5.3. Pharmacodynamics **201**
Appendix A49.5.4. Safety **201**
Appendix A49.5.5. Long-term **202**

Appendix A49.6. Summary **202**

Appendix A50. Study 148-361: A 12-week, double-blind, placebo controlled, parallel group, multi-centre study

followed by a 40 week open label extension to evaluate the efficacy and safety of UK-92,480 (sildenafil) in patients with erectile dysfunction. 203

Appendix A50.1. Source documents 203

Appendix A50.2. Investigators 203

Appendix A50.3. Study dates 203

Appendix A50.4. Study design 203

Appendix A50.5. Results 204
Appendix A50.5.1. Conduct 204
Appendix A50.5.2. Effectiveness 204
Appendix A50.5.3. Safety 205
Appendix A50.5.4. Long-term 205

Appendix A50.6. Summary 205

Appendix A51. Study 148-363: A double-blind, randomised, placebo-controlled, parallel group, multi-centre, flexible dose escalation study to assess the efficacy and safety of UK-92,480 administered over six months to male patients with erectile dysfunction. 206

Appendix A51.1. Source documents 206

Appendix A51.2. Investigators 206

Appendix A51.3. Study dates 206

Appendix A51.4. Study design 206

Appendix A51.5. Results 207
Appendix A51.5.1. Conduct 207
Appendix A51.5.2. Effectiveness 209
Appendix A51.5.3. Safety 211
Appendix A51.5.4. Long-term 211

Appendix A51.6. Summary 211

Appendix A52. Study 148-364: A double-blind, randomised, placebo-controlled, parallel group, multi-centre study to assess the efficacy and safety of fixed doses of sildenafil administered for three months to male patients with erectile dysfunction. 212

Appendix A52.1. Source documents 212

Appendix A52.2. Investigators 212

Appendix A52.3. Study dates 212

Appendix A52.4. Study design 212

Appendix A52.5. Results 213
Appendix A52.5.1. Conduct 213
Appendix A52.5.2. Effectiveness 215
Appendix A52.5.3. Safety 217

Appendix A52.6. Summary 217

Appendix A53. Study 148-367: A double-blind, randomised, placebo-controlled, two way cross-over, flexible dose study to assess the efficacy and safety of oral doses of sildenafil in patients with erectile dysfunction caused by traumatic injuries to the spinal cord. 218

Appendix A53.1. Source documents 218

Appendix A53.2. Investigators 218

Appendix A53.3. Study dates 218

Appendix A53.4. Study design 218

Appendix A53.5. Results 219
Appendix A53.5.1. Conduct 219
Appendix A53.5.2. Effectiveness 220
Appendix A53.5.3. Safety 221

Appendix A53.6. Summary 221

Appendix A54. Study 148-369: A double blind, randomised, placebo controlled, sequential design, two way crossover study to investigate the duration of action of a single oral dose of sildenafil (100 mg) on penile erectile activity during visual sexual stimulation in patients with male erectile dysfunction without an established organic cause. 222

Appendix A54.1. Source documents 222

Appendix A54.2. Investigators 222

Appendix A54.3. Study dates 222

Appendix A54.4. Study design 222

Appendix A54.5. Results 222
Appendix A54.5.1. Conduct 222
Appendix A54.5.2. Pharmacokinetics 222
Appendix A54.5.3. Pharmacodynamics 222
Appendix A54.5.4. Safety 222

Appendix A54.6. Summary 222

Appendix A55. Study 148-401: Statistical report a psychometric validation of the international index of erectile function (IIEF) in male patients with erectile dysfunction and age-matched controls 223

Appendix A55.1. Source documents 223

Appendix A55.2. Investigators 223

Appendix A55.3. Study dates 223

Appendix A55.4. Study design 223

Appendix A55.5. Results 223
Appendix A55.5.1. Conduct 223
Appendix A55.5.2. Validation 223

Appendix A56. Study 148-451: A study to generate sexual function and quality of life data in male subjects who do not have a diagnosis of erectile dysfunction. 224

Appendix A56.1. Source documents 224

Appendix A56.2. Investigators 224

Appendix A56.3. Study dates 224

Appendix A56.4. Study design 224

Appendix A56.5. Results 224
Appendix A56.5.1. Effectiveness 224
Appendix A56.5.2. Safety 224

List of tables

Table 1. Inhibition of phosphodiesterase forms by sildenafil. 4
Table 2. Single-dose pharmacokinetics in mammals. 5
Table 3. Safety factors based upon animal toxicity and human and animal pharmacokinetics. 7
Table 4. Controlled clinical trials of effectiveness. 8
Table 5. Clinical pharmacology trials. 9
Table 6. Long-term, open-label studies. 12
Table 7. Studies not reviewed in detail. 12
Table 8. Subjects exposed in clinical studies. 13
Table 9. Subjects by age in placebo-controlled and open-label studies. 13
Table 10. Etiology of erectile dysfunction in placebo-controlled and open-label studies. 13
Table 11. Baseline disease incidence (%) in placebo-controlled and open-label studies. 14
Table 12. Study drug exposure (doses) in studies 148-102 and 148-361. 14
Table 13. Planned exposure (weeks) in placebo-controlled fixed-dose studies. 14
Table 14. Composition (mg) of sildenafil tablets. 22
Table 15. Fixed-dose studies utilizing the IIEF. 28
Table 16. ITT analyses of IIEF questions 3 and 4 (fixed-dose studies). 29
Table 17. Sub-group analyses of IIEF questions 3 and 4 (Studies 148-102 and 148-364). 29
Table 18. ITT analyses of supportive IIEF questions at week 12 (fixed-dose studies). 30
Table 19. Successful intercourse by event logs (fixed-dose studies). 32
Table 20. Titration studies utilizing the IIEF. 32
Table 21. ITT analyses of IIEF questions 3 and 4 (titration studies). 33
Table 22. Sub-group analyses of IIEF questions 3 and 4 (Studies 148-103 and 148-363). 33
Table 23. ITT analyses of supportive IIEF questions at week 12 (titration studies). 34
Table 24. Successful intercourse by event logs (titration studies). 35
Table 25. Effectiveness in organic erectile dysfunction. 37
Table 26. Effectiveness in psychogenic erectile dysfunction. 37
Table 27. ITT analyses of IIEF questions 3 and 4 (Study 148-104). 38
Table 28. Effectiveness in diabetics with erectile dysfunction. 38
Table 29. Deaths on or within 30 days of study drug. 41
Table 30. Withdrawals from placebo-controlled studies. 42
Table 31. Withdrawals from open-label studies. 43
Table 32. Adverse events leading to withdrawal from placebo-controlled studies. 43
Table 33. Adverse events leading to withdrawal from open-label studies 47
Table 34. Dose-relatedness of common adverse events in placebo-controlled studies. 49
Table 35. Percentage of subjects with common adverse events in flexible-dosing studies. 49
Table 36. Hepatic function abnormalities in placebo-controlled studies. 50
Table 37. Potentially clinically significant shifts in electrolytes in placebo-controlled studies. 51
Table 38. Potentially clinically significant shifts in hematologic parameters in placebo-controlled studies. 51
Table 39. Relationship between dose at calcium level (Studies 102, 103, 363, and 364). 51
Table 40. Summary of median changes in vital signs in placebo-controlled studies. 52
Table 41. Disappearance half-lives for sildenafil in hepatic microsomes (Report DM2). 71
Table 42. P450 inhibitors (Report DM3). 71
Table 43. UK-103,320 formation in human liver microsomes (Report DM3). 73
Table 44. Correlation between rate of UK-103,320 formation and P450 isoform activity (Report DM3). 73
Table 45. Inhibition of CYP isoforms by sildenafil (Report DM4). 73
Table 46. Inhibition of CYP isoforms by UK-103-320 (Report DM5). 74
Table 47. Pharmacokinetic parameters (mean±SD) for final sildenafil model. 78
Table 48. Effect of addition of covariates to basic sildenafil model (test data). 78
Table 49. Effect of changes in covariates on pharmacokinetic model for sildenafil (final dataset). 79
Table 50. Effect of deletion of studies from final pharmacokinetic model for sildenafil. 79
Table 51. Effect of addition of covariates to basic UK-103,320 model (test data). 79
Table 52. Effect of changes in covariates on pharmacokinetic model for UK-103,320 (final dataset). 81
Table 53. Effect of deletion of studies from final pharmacokinetic model for UK-103,320. 81

Table 54. Effect of additive or proportional E_{max} and estimation method on fit to pharmacodynamic model. 82
Table 55. Effect of deletion of studies from final pharmacodynamic model. 82
Table 56. Estimated D_{50} for question 3, by study. 83
Table 57. Effect of deletion of studies from final pharmacodynamic model. 83
Table 58. Estimated D_{50} for question 4, by study. 84
Table 59. Pharmacokinetic parameters for sildenafil and UK-103,320 (Study 148-001). 91
Table 60. Drug supplies (Study 148-002). 92
Table 61. Assay for sildenafil and UK-103,320 (Study 148-002). 92
Table 62. Pharmacokinetic parameters (Study 148-002). 93
Table 63. Drug supplies (Study 148-003). 94
Table 64. Assay for sildenafil and UK-103,320 (Study 148-003). 94
Table 65. Pharmacokinetic parameters (Study 148-003). 95
Table 66. Drug supplies (Study 148-004). 96
Table 67. Pharmacokinetic parameters (Study 148-004). 97
Table 68. Drug supplies (Study 148-101/101B). 99
Table 69. Demographics (Study 148-101/101B). 100
Table 70. Protocol violations (Study 148-101/101B). 100
Table 71. ITT analyses of EF question 1 (Study 148-101/101B). 101
Table 72. Drug supplies (Study 148-101C). 102
Table 73. Drug supplies (Study 148-102). 104
Table 74. Demographics (Study 148-102). 106
Table 75. Protocol violations (Study 148-102). 106
Table 76. ITT analyses of IIEF questions 3 and 4 (Study 148-102). 107
Table 77. ITT analyses of non-primary IIEF questions at week 12 (Study 148-102). 108
Table 78. Successful intercourse by event logs (Study 148-102). 109
Table 79. ITT shift analyses of IIEF questions 3 and 4 at week 24 (Study 148-102). 109
Table 80. Sub-group analyses of IIEF questions 3 and 4 (Study 148-102). 110
Table 81. Drug supplies (Study 148-103). 111
Table 82. Demographics (Study 148-103). 113
Table 83. Protocol violations (Study 148-103). 113
Table 84. ITT analyses of IIEF questions 3 and 4 (Study 148-103). 114
Table 85. ITT analyses of non-primary IIEF questions at week 12 (Study 148-103). 115
Table 86. Successful intercourse by event logs (Study 148-103). 115
Table 87. ITT shift analyses of IIEF questions 3 and 4 at week 24 (Study 148-103). 116
Table 88. Sub-group analyses of IIEF questions 3 and 4 (Study 148-103). 116
Table 89. Drug supplies (Study 148-104). 118
Table 90. Demographics (Study 148-104). 120
Table 91. Protocol violations (Study 148-104). 120
Table 92. ITT analyses of IIEF questions 3 and 4 (Study 148-104). 121
Table 93. ITT analyses of non-primary IIEF questions at week 12 (Study 148-104). 122
Table 94. Successful intercourse by event logs (Study 148-104). 122
Table 95. Drug supplies (Study 148-105). 124
Table 96. ITT analyses of Rigiscan data (Study 148-105). 125
Table 97. Plasma levels (±SD) of sildenafil (Study 148-105). 125
Table 98. Drug supplies (Study 148-106). 126
Table 99. Demographics (Study 148-106). 128
Table 100. Protocol violations (Study 148-106). 128
Table 101. ITT analyses of IIEF questions 3 and 4 (Study 148-106). 129
Table 102. ITT analyses of non-primary IIEF questions at week 12 (Study 148-106). 129
Table 103. Pharmacokinetic parameters after IV dosing (Study 148-203). 132
Table 104. Pharmacokinetic parameters after single and multiple dosing (Study 148-207). 137
Table 105. Pharmacokinetic parameters for sildenafil after IV and oral administration (Study 148-208). 139
Table 106. Pharmacokinetic parameters (Study 148-214). 144
Table 107. Pharmacokinetic parameters for total radioactivity after IV and oral dosing (Study 148-215). 146

Table 108. Pharmacokinetic parameters for plasma sildenafil after IV and oral dosing (Study 148-215). 147
Table 109. Pharmacokinetic parameters for sildenafil metabolites after IV and oral dosing (Study 148-215). ... 147
Table 110. Bleeding time (Study 148-216). 150
Table 111. Pharmacokinetic parameters for sildenafil, UK-103,320, and ethanol (Study 148-217). 152
Table 112. Drug supplies (Study 148-218). 153
Table 113. Pharmacokinetic parameters for tolbutamide (Study 148-218). 154
Table 114. Urinary excretion of tolbutamide metabolites (Study 148-218). 154
Table 115. Drug supplies (Study 148-219). 155
Table 116. Bleeding time and prothrombin time (Study 148-219). 156
Table 117. Pharmacokinetic parameters (Study 148-221). 158
Table 118. Bleeding time (Study 148-222). 159
Table 119. Effects on vital signs (Study 148-225). 162
Table 120. Pharmacokinetic parameters (Study 148-226). 164
Table 121. Pharmacokinetic parameters for sildenafil and UK-103,320 (Study 148-227). 166
Table 122. Drug supplies (Study 148-228). 167
Table 123. Pharmacokinetic parameters for sildenafil and UK-103,320 (Study 148-228). 168
Table 124. Test of dose-proportionality for AUC and C_{max} of sildenafil (Study 148-228). 168
Table 125. Pharmacokinetic parameters (Study 148-229). 171
Table 126. Vital signs (Study 148-230). 173
Table 127. Vital signs (Study 148-231). 175
Table 128. Pharmacokinetic parameters (Study 148-232). 177
Table 129. Color discrimination error scores for normals (Study 148-232). 178
Table 130. Pharmacokinetic parameters (Study 148-234). 180
Table 131. Hemodynamic data at highest dose (Study 148-301). 181
Table 132. Penile plethysmography (Study 148-350). 183
Table 133. Penile plethysmography (Study 148-351). 184
Table 134. Drug supplies (Study 148-353). 186
Table 135. Demographics (Study 148-353). 187
Table 136. Protocol violations (Study 148-353). 187
Table 137. ITT analyses of global effectiveness data (Study 148-353). 187
Table 138. ITT analyses of non-primary SFQ questions at week 4 (Study 148-353). 188
Table 139. Drug supplies (Study 148-354A). 189
Table 140. Drug supplies (Study 148-355). 191
Table 141. Drug supplies (Study 148-356). 193
Table 142. Drug supplies (Study 148-357). 195
Table 143. Effectiveness data (Study 148-357). 196
Table 144. Drug supplies (Study 148-358). 197
Table 145. Drug supplies (Study 148-359). 199
Table 146. Drug supplies (Study 148-361). 203
Table 147. Demographics (Study 148-361). 204
Table 148. ITT analyses of IIEF question1 (Study 148-361). 204
Table 149. ITT analyses of non-primary IIEF questions at week 12 (Study 148-361). 205
Table 150. Drug supplies (Study 148-363). 206
Table 151. Demographics (Study 148-363). 208
Table 152. Protocol violations (Study 148-363). 208
Table 153. ITT analyses of IIEF questions 3 and 4 (Study 148-363). 209
Table 154. ITT analyses of non-primary IIEF questions at week 12 (Study 148-363). 210
Table 155. Successful intercourse by event logs (Study 148-363). 210
Table 156. Sub-group analyses of IIEF questions 3 and 4 (Study 148-363). 211
Table 157. Drug supplies (Study 148-364). 212
Table 158. Demographics (Study 148-364). 214
Table 159. Protocol violations (Study 148-364). 214
Table 160. ITT analyses of IIEF questions 3 and 4 (Study 148-364). 215

Table 161. ITT analyses of non-primary IIEF questions at week 12 (Study 148-364). 216
Table 162. Successful intercourse by event logs (Study 148-364). 216
Table 163. Sub-group analyses of IIEF questions 3 and 4 (Study 148-364). 217
Table 164. Drug supplies (Study 148-367). 218
Table 165. Demographics (Study 148-367). 219
Table 166. Protocol violations (Study 148-367). 220
Table 167. ITT analyses of IIEF questions at weeks 6 and 12 (Study 148-367). 220

List of figures

Figure 1. Structure of sildenafil. 3
Figure 2. Metabolism of sildenafil (percentages in excreta). 17
Figure 3. Dissolution of sildenafil 100-mg tablets 23
Figure 4. Dissolution of sildenafil 25-mg tablets at 100 rpm. 23
Figure 5. Dissolution of 25-, 50-, and 100-mg tablets with and without film coating. 24
Figure 6. ECG data (Studies 148-001, -004, -201, and -201A. 53
Figure 7. Presumed pharmacological basis for actions of sildenafil. 54
Figure 8. Effect of cytochrome P450 inhibitors on metabolism of sildenafil (Report DM3). 72
Figure 9. Correlations between observed UK-103,320 formation and that predicted by CYP 3A4 and 2C9 combined (Report DM3). 72
Figure 10. Rate of formation of UK-103,320 in cell lines expressing CYP 1A2, 2C9, 2D6, 2E1, and 3A4 (Report DM3). 72
Figure 11. Partial metabolic scheme for UK-103,320 in human liver microsomes (Report DM5). 74
Figure 12. Inhibition of metabolism of testosterone and terfenadine by sildenafil (Report DM34). 74
Figure 13. Plasma levels of sildenafil and UK-103-320 (multiple studies). 76
Figure 14. Residuals from final model of sildenafil pharmacokinetics. 77
Figure 15. Covariates in model of sildenafil pharmacokinetics. 77
Figure 16. Goodness of fit for final model of sildenafil pharmacokinetics. 78
Figure 17. Goodness of fit for final model of UK-103,320 pharmacokinetics. 80
Figure 18. Selected covariate relationships in the final model of UK-103,320 pharmacokinetics. 80
Figure 19. Change in response to question 3. 82
Figure 20. Final dose-response model by baseline for question 3. 83
Figure 21. Change in response to question 4. 84
Figure 22. Final dose-response model by baseline for question 4. 84
Figure 23. Modeled dependence of selected adverse events on dose, AUC, and C_{max}. 85
Figure 24. Plasma sildenafil and UK-103,320 levels (Study 148-001). 90
Figure 25. Relationships among pharmacokinetic parameters (Study 148-001). 91
Figure 26. Plasma levels of sildenafil and UK-103,320 (Study 148-002). 93
Figure 27. Plasma levels of sildenafil and UK-103,320 (Study 148-003). 95
Figure 28. Mean plasma levels of sildenafil and UK-103,320 (Study 148-004). 96
Figure 29. Pharmacokinetic parameters by dose (Study 148-004). 97
Figure 30. Pharmacodynamic effects at 800 mg, while standing (Study 148-004). 97
Figure 31. Exposure to study drug (Study 148-101C). 103
Figure 32. Disposition of subjects (Study 148-102). 107
Figure 33. Disposition of subjects (Study 148-103). 114
Figure 34. Disposition of subjects (Study 148-104). 121
Figure 35. Plasma levels of sildenafil and UK-103,320 after IV dosing (Study 148-203). 132
Figure 36. Log-log plots of C_{max} and AUC for sildenafil after IV dosing (Study 148-203). 132
Figure 37. Plasma sildenafil levels after single and multiple dosing (Study 148-207). 136
Figure 38. Single-dose AUC and C_{max} for sildenafil by dose (Study 148-207). 136
Figure 39. Plasma levels of UK-103,320 after single and multiple doses of sildenafil 75 mg (Study 148-207). 137
Figure 40. Mean plasma sildenafil after IV and oral dosing (Study 148-208). 140
Figure 41. V_{ss} and clearance by body weight (Study 148-208). 140
Figure 42. Plasma levels of sildenafil and UK-103,320 by time after dosing and degree of renal impairment (Study 148-214). 143
Figure 43. Clearance and C_{max} for sildenafil as a function of creatinine clearance (Study 148-214). 143
Figure 44. Clearance and C_{max} for sildenafil as a function of age (Study 148-214). 144
Figure 45. Plasma and whole-blood levels of total radioactivity after IV and oral dosing (Study 148-215). ..146
Figure 46. Plasma levels of total radioactivity after IV and oral dosing (Study 148-215). 147
Figure 47. Plasma levels of sildenafil metabolites after IV and oral dosing (Study 148-215). 147
Figure 48. Proposed routes of metabolism for sildenafil (Study 148-215). 148
Figure 49. Plasma levels of sildenafil and UK-103,320 after sildenafil ± ethanol (Study 148-217). 152
Figure 50. Plasma levels of ethanol after sildenafil ± ethanol (Study 148-217). 152

Figure 51. Plasma levels of tolbutamide (Study 148-218). 154
Figure 52. Individual prothrombin times on placebo and sildenafil (Study 148-219) 156
Figure 53. Plasma levels of sildenafil and UK-103,320 (Study 148-221). 158
Figure 54. Ln(AUC) as a function of Child-Pugh score (Study 148-221). 158
Figure 55. Color discrimination scores (A) by dose and (B) by color at 200 mg (Study 148-223). 160
Figure 56. Plasma levels of sildenafil and UK-103,320 (Study 148-226). 164
Figure 57. Plasma sildenafil and UK-103,320 levels (Study 148-227). 166
Figure 58. Plasma sildenafil and UK-103,320 levels (Study 148-228). 168
Figure 59. Concentrations of sildenafil and UK-103,320 in plasma (Study 148-229). 171
Figure 60. Concentrations of sildenafil and UK-103,320 in semen (Study 148-229). 171
Figure 61. Plasma-semen relationships for sildenafil and UK-103,320 (Study 148-229). 172
Figure 62. Changes in standing blood pressure (Study 148-230). 174
Figure 63. Changes in heart rate (Study 148-230). 174
Figure 64. Changes in sitting vital signs (Study 148-231). 176
Figure 65. Color distribution of color discrimination errors on sildenafil at 2 hours (Study 148-232). 178
Figure 66. Plasma levels of sildenafil and UK-103,320 (Study 148-234). 180
Figure 67. Exposure to study drug (Study 148-354A). 190
Figure 68. Dependence of erectile response on plasma sildenafil (Study 148-360). 201
Figure 69. Disposition of subjects (Study 148-363). 209
Figure 70. Disposition of subjects (Study 148-364). 215